Accurately assessing the contribution of cytochrome P450 (CYP) isoforms to overall metabolic clearance is important for prediction of clinical drug-drug interaction (DDI). The relative activity factor (RAF) approach in CYP reaction phenotyping assumes that the interaction between CYP-selective probes and testing systems is the same as to drug candidate with those systems. To test this assumption, Intersystem Clearance Ratio (ICR) was created to evaluate the difference in values between RAF-scaled intrinsic clearance (CL int ) and measured CL int in human liver microsomes (HLM). RAF value for CYP3A4 or CYP2C9 derived from a particular CYPselective probe reaction was applied to calculate RAF-scaled CL int for other probe reactions of the same CYP isoform in a crossover manner and compared with the measured HLM CL int .
DMD # 73510

Introduction
Cytochrome P450 (CYP) enzymes are well known for their importance in metabolism of the majority of drugs (Coon, 2005; Guengerich, 2006) . In the drug development process, quantification of contributions of CYP isoforms toward the overall metabolism of a drug candidate is necessary for evaluating the risk of the drug candidate as a potential victim in drugdrug interaction (DDI). A commonly used method for such assessment is the relative activity factor (RAF) approach using recombinant human CYP (rCYP) and human liver microsomes (HLM). In this approach, the intrinsic clearance (CL int ) of a CYP-selective probe reaction is assessed in both systems (rCYP and HLM) to establish the RAF for each CYP isoform. The determination of RAF is highly depended on the HLM batch, rCYP expression quality, and the incubation conditions. Therefore, the RAF values are highly diverse among labs and specific to the experimental conditions applied in each lab as illustrated by several investigators (Venkatakrishnan et al., 2001; Soars et al., 2003; Uttamsingh et al., 2005; Emoto and Iwasaki, 2007) . However, once the RAF values are established, the RAF of each CYP isoform can be subsequently applied to the CL int of a potential drug candidate measured in the rCYP system to assess each isoform's relative contribution to metabolism in HLM, as long as the conditions are kept consistent (Harper and Brassil, 2008; Bohnert et al., 2016) . In this process, it is assumed that scaling CL int from rCYP to HLM is consistent between the CYP-selective probe reaction and the metabolism of the drug candidate by that CYP isoform. However, to our knowledge, there has been no study to test this assumption. Furthermore, multiple binding sites with diverse substrate selectivity have been recognized for several CYP isoforms, especially CYP2C9 and CYP3A4, which are important in drug metabolism (Galetin et al., 2003; Kumar et al., 2006) .
Based on this rather unique property of CYP, it is conceivable that a drug candidate may not This article has not been copyedited and formatted. The final version may differ from this version. always interact with its binding site in the same way as the probe from which the RAF was derived. In the present study, diverse probe substrates were used to establish RAF values for CYP3A4 (midazolam, testosterone, and nifedipine) and CYP2C9 (S-warfarin, diclofenac, and tolbutamide). The RAF value generated from a particular probe was exploited to generate the RAF-scaled CL int from rCYP to HLM (RAF-scaled CL int ) for the other probe reactions of the same CYP isoform in a crossover manner. The RAF-scaled CL int values from rCYP were then compared with the measured CL int in HLM (HLM CL int ), and an Intersystem Clearance Ratio (ICR) was created to gauge the difference between these two values. Additionally, RAF values were applied to three model drugs to determine the relative contributions of CYP3A4 versus CYP2C9 to their overall metabolic clearance. The objective of the current study was to demonstrate the impact of RAF probe substrate selection on determination of the fractional contributions of enzymes involved in overall metabolic clearance (f m ) of CYP isoform. The potential application of ICR as a tool to identify the appropriate probe for RAF approach in CYP phenotyping was also explored.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Materials
Probe substrates and metabolites, losartan, (R)-propranolol, and sildenafil were purchased from Sigma-Aldrich (St. Louis, MO). Meloxicam was obtained from Santa Cruz Biotech (Santa Cruz, CA). Mixed gender pooled HLM was purchased from XenoTech (Lenexa, KS). rCYP isoforms (Supersomes™) and potassium phosphate buffer (PPB) were purchased from Corning Life Sciences (Tewksbury, MA). Reduced β -NADPH was purchased from Oriental Yeast Company (Andover, MA). All other chemicals, reagents, and solvents used in the analytical process were of either analytical or high-performance liquid chromatography (HPLC) grade.
Analytical
Analyses of probe reactions were performed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The mass spectrometer, AB Sciex 4000 QTrap triple quadrupole mass spectrometer (Framingham, MA), was interfaced with Shimadzu HPLC systems including LC-10AD binary pumps and SIL-HTC autosampler (Shimadzu Corporation, Kyoto, Japan). The HPLC column used was Zorbax XDB-C18 5µ 2.1 x 50 mm (Agilent, Santa Clara, CA). HPLC resolution was achieved with a gradient consisting of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). The gradient consisted of the following steps: t = 0 min, %B = 1; t = 3 min, %B = 80; t = 4 min, %B = 99; t = 4.1 min, %B = 1, and a total run time of 7.5 min. The flow rate was 500 µl/min and the injection volume was 5-10 µl. The mass spectrometer was operated in positive ion mode using Turbo Spray ionization source. The ionization spray voltage was set at 5000 V and the source temperature was maintained at 650 ºC. The CYP-selective probe reactions were assessed in the multiple reaction This article has not been copyedited and formatted. The final version may differ from this version. 
Protein Binding
Final concentrations of probe substrates were set to the apparent substrate concentration at which the reaction rate is half of maximal velocity (K m ), and those of model drugs were 0.5 µmol/l.
Probe substrate or model drugs were spiked with 0.5 mg/ml HLM or 50 pmol/ml rCYP isoforms.
Three hundred microliters of each sample was added to the dialysis membrane side of the Rapid Equilibrium Devices ® in duplicate; 500 μ l of PPB (100 mmol/l, pH 7.4) was added to the outer well of the Rapid Equilibrium Devices 
RAF Determination
The incubations were carried out in deep-well 96-well plates containing 0.5 mg/ml HLM or 50 pmol/ml rCYP isoforms, probe substrates, and PPB (100 mmol/l, pH 7.4) at a final volume of 
Metabolism of Losartan, Meloxicam, and Sildenafil
The incubations were carried out in deep-well 96-well plates containing 0.5 mg/ml HLM or 50 pmol/ml rCYP isoforms, 0. 
Data Analysis and Calculations
For each CYP-selective probe reaction, the K m and V max values were measured following typical
Michaelis-Menten kinetics. The CL int for each system was calculated from the measured V max and K m . The K m value was corrected using the unbound fraction (f u ) of the substrate in both rCYP and HLM systems. Based on these measured values, the unbound CL int (CL int,u ) for each probe was calculated.
The RAF for each CYP isoform was established based on the CL int obtained in rCYP and HLM.
Equation 1 The ICR was defined as the following equation.
Equation 2 The relative contribution of a CYP isoform to total CYP-mediated clearance was calculated as reported in the literature (Bohnert et al., 2016 Supplementary) . Results
Establishment of RAF
All CYP-selective probe reactions are shown in Table 1 . For CYP2C9 and CYP3A4, three probe reactions were used. For CYP1A2, CYP2C19, and CYP2D6, a single probe reaction was used.
The RAF value for each probe was generated based on the ratio of CL int,u in rCYP and HLM 
Cross-System Comparison of CL int,u for Probe Reactions of CYP2C9 and CYP3A4
For each probe reaction of CYP2C9 or CYP3A4, the unbound HLM CL int was compared with the unbound RAF-scaled CL int obtained from the measured CL int,u and the established RAF in each rCYP. When the RAF generated from a probe reaction (e.g. tolbutamide for CYP2C9 or midazolam for CYP3A4) was applied to the probe itself, the ICR between unbound RAF-scaled CL int and HLM CL int , as calculated using Equation 2, was exactly equal to the unity value (1) as expected. However, when a particular RAF generated from a probe substrate was applied to the other probes of the same CYP isoform, ICR values showed significant deviation from the unity value ( Fig. 1) . For example, when the RAF value derived from tolbutamide was applied to other CYP2C9-selective probes such as diclofenac and S-warfarin, the ICR values were 0.4 and 0.6, respectively (Fig. 1B) . Such deviations of ICR from unity were more marked among the This article has not been copyedited and formatted. The final version may differ from this version. CYP3A4 probes, especially testosterone. The ICR value was 31 and 25 when the RAF value generated from midazolam and nifedipine, respectively, was applied to testosterone 6β-hydroxylation ( Fig. 1D and 1E ).
Impact of Selection of Probe Substrate Combination on CYP Phenotyping Assessments
RAF values were applied to three model drugs (losartan, meloxicam, and sildenafil) to determine the relative contributions of CYP isoforms to their overall metabolic clearance. For each of the model drugs, the CL int,u and f u values were measured in HLM and in each rCYP isoform; the results are shown in Table 2 . The CL int,u of each rCYP was then adjusted with the established RAF and summed up to calculate unbound RAF-scaled CL int , which was compared with the unbound HLM CL int to generate the ICR value. Since three diverse probe substrates were used to generate RAF values for CYP2C9 and CYP3A4, there were a total of nine different combinations of the unbound RAF-scaled CL int and ICR for each model drug (Table 3) .
Applying the values obtained from each combination to Equation 3, the f m of each CYP isoform was determined for losartan, meloxicam, and sildenafil (Fig. 2, 3 , and 4, respectively). The estimated f m values, specifically for CYP2C9 and CYP3A4, varied considerably depending on the RAF values derived from various combinations of CYP-selective probes. Generally, the most significant impact on f m occurred when various CYP3A4 probes were applied, while less impact was demonstrated among the CYP2C9 probes. In the case of losartan, with RAF derived from testosterone that was fixed for CYP3A4, the assessment of relative f m by CYP isoforms did not vary greatly based on the selection of probes for CYP2C9. Using RAF generated from diclofenac, tolbutamide, and S-warfarin for CYP2C9, the results consistently showed the predominance of a CYP2C9 contribution with f m values of 87%, 72%, and 82%; and a minor This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A and 2B ; Supplemental Table 1 ). Similar results were also observed with meloxicam. When RAF derived from testosterone was fixed for CYP3A4, combined with the RAF for CYP2C9 derived from diclofenac, tolbutamide, and Swarfarin, the f m of CYP2C9 was assessed as 69%, 47%, and 61%; and the f m of CYP3A4 was assessed as 16%, 28%, and 21%, respectively ( Fig. 3C ; Supplemental Table 2 ). Applying RAF values from other CYP3A4 probes would remarkably underestimate the contribution of CYP2C9
for meloxicam metabolism with f m values ranging from 5% to 14%, which were significantly minor relative to CYP3A4 contribution ranging from 83% to 92% ( Fig. 3A and 3B ;
Supplemental Table 2 ). Among all combinations of probe substrates, the ICR values closest to the unity were associated with using RAF derived from testosterone for CYP3A4 and diclofenac for CYP2C9 for losartan and using RAF derived from testosterone for CYP3A4 and tolbutamide for CYP2C9 for meloxicam (Table 3 ). In the case of sildenafil, any combination of probes assigned the predominant contribution of CYP3A4 over CYP2C9 in its overall metabolism ( Fig.   4 ; Supplemental Table 3 ).
Discussion
For drug safety concerns, risk assessments for potential metabolism-based DDI are mandated by regulatory agencies before the initiation of advanced clinical trials (FDA, 2012; EMA, 2012) .
One of the crucial aspects of DDI is the potential for a drug to become the victim of a coadministered drug capable of modulating its metabolic clearance. Inhibition or induction of the enzymes involved in metabolic clearance can potentially increase or decrease the intended exposure of the target drug and lead to toxicity or lack of efficacy. To avoid such undesired consequences, assessment for DDI requires an accurate measurement of the f m of the victim drug. Theoretically, for a victim drug that undergoes substantial metabolism, the magnitude of impact on its systemic exposure by a perpetrator of a metabolic enzyme is governed by the f m for the enzyme (Zhang et al., 2007) . Since the prediction of DDI for a victim drug is so sensitive to the f m value, it is desirable to obtain the best estimate for any enzymes involved in overall metabolic clearance (Bohnert et al., 2016) . However, CYP enzymes often present significant challenges to phenotyping assessments that determine the f m value of each isoform. One of such challenges is frequently encountered during the application of RAF approach with rCYP and HLM systems.
In this study, we challenged the assumption that RAF value generated using a particular CYPselective probe reaction can always accurately scale the CL int from rCYP to HLM. RAF value derived from a particular probe reaction was applied to other probe reactions of the same CYP isoform. The RAF-scaled CL int was then compared to the measured HLM CL int to generate an ICR. In an ideal scenario, the ICR would always be equal to the unity value for the original CYP probe from which the RAF was derived. However, when applying the RAF to other probes of This article has not been copyedited and formatted. The final version may differ from this version. the same CYP, there were significant deviations of the ICR from the unity value (Fig. 1), suggesting the inadequacy of a specific RAF for scaling CL int of other probes that might bind to the same enzyme but at different binding sites. Although the potential cause of such deviation is still unknown and beyond the scope of the current study, it is clear that protein binding in rCYP or HLM systems played an insignificant role, as the CL int values used in the current study were already corrected for the unbound fraction of each probe substrate in each system ( Table 1) . The results indeed demonstrate the limitations of the commonly used RAF approach with a single probe for each CYP isoform. Since the CL int scaled from rCYP has been widely used for the assessment of f m of the CYP to the overall clearance in HLM, our results further highlight the impact of probe substrate selection on the outcome of CYP reaction phenotyping using the RAF approach.
To further illustrate the impact on CYP phenotyping results, we selected losartan, meloxicam, and sildenafil as model drugs. CYP3A4 and CYP2C9 have been reported as the enzymes involved in oxidative metabolism of these drugs (Sica et al., 2005; Gates et al., 2005; Hyland et al., 2001) . In these case studies, ICR was also generated by comparing the sum of RAF-scaled CL int values obtained from rCYP and from direct measurement in HLM (HLM CL int ). Ideally, if the interaction between the CYP-selective probe and the enzyme systems completely represents the interaction between the drug candidate and the same enzyme systems, an ICR equal to the unity value would be expected. However, deviation of ICR from unity has frequently been observed in CYP phenotyping using RAF or similar approaches. ICR that is less than unity (ICR < 1) is often attributed to potential involvement of drug metabolism enzymes other than the CYP isoforms included in the study. On the other hand, ICR that is greater than unity (ICR > 1) is (Table 3) . Furthermore, assessing an ICR close to the unity value may assist the selection of the most appropriate probe substrates for drug candidate phenotyping studies. This potential application was demonstrated with both losartan and meloxicam. Significantly higher contributions of CYP2C9 over CYP3A4 were reported for both losartan (Yasar et al., 2001; Sica et al., 2005) and meloxicam (Chesné et al., 1998; Türck et al., 1996) based on in vitro CYPselective inhibitor approaches and clinical observations. In the current study, ICR values were observed to be closer to the unity value for these drugs when testosterone for CYP3A4 and diclofenac or tolbutamide for CYP2C9 was selected as the probe substrates to derive RAF values. For these two model drugs, such combinations of probes for RAF produced assessments of relative contributions of CYP2C9 and CYP3A4 that were consistent with results previously reported using other approaches ( Fig. 2C and 3C ). In contrast, other combinations of probes associated with much greater ICR values would have attributed predominant contributions of their metabolic clearances to CYP3A4. Such results would strongly contradict previous reports on losartan and meloxicam ( Fig. 2A, 2B , 3A, and 3B). The significant impact of probe substrate selection for RAF on the assessment of f m was also demonstrated in the case of sildenafil, in which CYP3A4 was reported as the predominant contributor to metabolic clearance in comparison to CYP2C9 (Hyland et al., 2001; Muirhead et al., 2000) . Although all combinations of probes confirmed that CYP3A4 was the major isoform contributing to the metabolism of sildenafil, f m of CYP2C9 was much higher when RAF values derived from testosterone were used as the probe for CYP3A4 (Fig. 4) . To our knowledge, this is the first systematic investigation to explore the impact of CYP probe substrate selection on the result of CYP This article has not been copyedited and formatted. The final version may differ from this version. Physiologically based pharmacokinetic (PBPK) modeling and simulation has evolved as an important tool for drug development and regulatory submission (Zhao et al., 2012; Jones et al., 2015) . Before extensive clinical trials, this tool can help improve predictions of pharmacokinetic and DDI in humans based on data generated from appropriately designed and conducted in vitro studies. The results obtained from such predictions are used not only for decision-making during drug development but also during the regulatory review process (Zhao et al, 2011) . The outcome of DDI predictions from PBPK modeling and simulation can impact critical decisions, such as whether to conduct or waive clinical DDI studies, and inclusions of drug labeling (Zhao et al., 2011; Jones et al., 2015) . However, the quality of PBPK modeling and simulation is highly dependent on the quality of input data. Therefore, the generation of reliable assessments of CYP contribution to metabolic clearance is essential to cultivating confidence in PBPK modeling and simulation prior to clinical trials. The current study demonstrated a significant impact of probe substrate selection on CYP phenotyping studies using the RAF approach to generate f m values.
This article has not been copyedited and formatted. The final version may differ from this version. Our results highlight the necessity of assessing RAF from diverse probe substrates for CYP isoforms, specifically CYP3A4 and CYP2C9. Considering the importance of f m in risk assessment of a drug as a potential DDI victim, the appropriate selection of probe substrates for RAF could have a significant impact on the accuracy of f m assessment and on the accuracy of DDI assessment using PBPK modeling and simulation. As a general guidance to CYP phenotyping, RAF values of a CYP isoform should be established with multiple probe substrates and applied respectively to the f m assessment for the drug candidate. The selection of suitable probe substrate may be determined by the closeness of the overall ICR to the unity value.
Although the current study focused on CYP3A4 and CYP2C9, the next steps would be to investigate the diverse probe substrates of other CYP isoforms and their potential impacts on the outcomes of CYP phenotyping using the RAF approach.
